BCAL Diagnostics (ASX:BDX) said its breast cancer diagnostic product, BREASTEST Plus will generate its first sales revenue this week, according to a Monday Australian bourse filing.
The company said it has been granted a diagnostic signature patent by IP Australia providing the diagnostic blood test kit intellectual property protection till 2043.
The company's shares jumped 17% on market close.